Weight Loss Drugs Like Ozempic Could Have Additional Health Benefit
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Could diabetes and weight loss drugs like Ozempic (semaglutide) also protect the brain from stroke damage—or even help prevent strokes entirely?
Three new studies suggest they might, with the potential of GLP-1 receptor agonists—such as Ozempic—extending beyond just blood sugar regulation and weight loss.
According to a May 2024 KFF Health Tracking Poll, approximately one in eight U.S. adults (12 percent) report having used a GLP-1 agonist.
Usage rates are notably higher among individuals with chronic health conditions: 43 percent of adults with diabetes, 25 percent with heart disease, and 22 percent of those who have been diagnosed as overweight or obese in the past five years have taken one of these medication.
Now, emerging research suggests they may also offer significant neurological benefits.
A stock image of woman injecting a Semaglutide Pen in her stomach.
A stock image of woman injecting a Semaglutide Pen in her stomach.
JNemchinova/iStock / Getty Images Plus
Lower Stroke Mortality in Ozempic Users
The first study, led by researchers at the University of Wisconsin-Madison, analyzed stroke outcomes among patients taking Ozempic. The team compared data from two large sources: the University of Wisconsin's health system and a global health collaborative.
Among more than two million stroke patients from the global dataset, those on Ozempic were found to have a dramatically lower initial death rate—just 5.26 percent compared to 21.61 percent for non-users.
Long-term survival rates also favored Ozempic users, with a 77.5 percent survival rate versus 30.95 percent for those not on the drug.
The university's own data mirrored this trend: stroke mortality among Ozempic users was less than 5 percent, compared to more than 26 percent in non-users.
Could Ozempic Reduce the Risk of Stroke?
A second study, also from the University of Wisconsin-Madison, looked at whether Ozempic could lower the chance of experiencing a stroke in the first place.
Researchers analyzed emergency department records nationwide, identifying individuals likely using Ozempic and comparing their stroke incidence rates.
The study found that potential Ozempic users had significantly lower odds of suffering a stroke.
The research team now hopes to confirm these findings using pharmacy records, which would more precisely track who is prescribed the drug.
Brain Bleed Protection and Cognitive Benefits
The final study, conducted by the University of Texas Medical Branch in Galveston, extended the investigation to brain hemorrhages—both spontaneous bleeds and those caused by aneurysms.
The researchers examined the health record of patients who had experienced a stroke or hemorrhage for up to two years after the event in question.
Their analysis indicated that GLP-1 agonists were associated with reduced risks of cognitive decline, seizures, repeat hemorrhages and death.
"This research could introduce a new perspective to the discussion of preventing and mitigating the devastating effects of stroke and related brain injuries," paper author and neurosurgeon Dr. Matias Costa said in a statement.
A Promising Frontier for GLP-1 Drugs
Dr. Ahmed Elbayomy, a research fellow in neurological surgery at the University of Wisconsin-Madison and lead author on two of the studies said in a statement: "More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding."
As use of semaglutide-based drugs like Ozempic and Wegovy continues to expand, the possibility that they might also protect the brain could usher in a new era of neurological prevention—offering more than just metabolic benefits.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about GLP-1 agonists? Let us know via health@newsweek.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
8 hours ago
- CNBC
Hims & Hers stock falls 10% on revenue miss
Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue. Here's how the company did based on average analysts' estimates compiled by LSEG: Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier. For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million. Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved. Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It's legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount. Hims & Hers will host its quarterly call with investors at 5 p.m. ET.
Newsweek
11 hours ago
- Newsweek
Map Shows Countries Where US Has Issued Fresh Travel Warnings
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. has issued new travel warnings in response to disease outbreaks in several countries, warning Americans to "practice enhanced precautions" when visiting the affected regions. On August 4, Centers for Disease Control and Prevention (CDC) issued a level 2 travel alert, part of its four-tier system, over global polio in several countries. Travelers are advised to make sure they are up to date with their polio vaccines. Anyone visiting the affected countries who previously completed the full, routine polio vaccine series may also receive a single, lifetime booster dose of polio vaccine. The list of affected countries includes Afghanistan, Algeria, Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Côte d'Ivoire (Ivory Coast), Democratic Republic of the Congo, Djibouti, Egypt, Ethiopia, Finland, French Guiana (France), Germany, Ghana, Guinea, Indonesia, Israel, the West Bank and Gaza, Kenya, Liberia, Niger, Nigeria, Pakistan, Papua New Guinea, Poland, Republic of South Sudan, Senegal, Sierra Leone, Somalia, Spain, Sudan, Tanzania, including Zanzibar, Uganda, United Kingdom, including England, Scotland, Wales, and Northern Ireland, Yemen and Zimbabwe. In the past month, the CDC also raised Level 2 travel alerts over outbreaks of chikungunya in China, confirmed and suspected cases of diphtheria in Guinea, and outbreaks of mpox in Liberia and Sierra Leone. The CDC ranks travel alerts from Level 1 ("Practice Usual Precautions") to Level 4 ("Avoid All Travel"). Level 2 urges travelers to take stronger precautions due to an elevated risk of infection. Why It Matters These advisories underscore the importance of Americans staying informed about health and safety risks when traveling overseas. Conditions such as mpox and diphtheria can worsen quickly if not managed properly. What To Know Chikungunya in China On August 1, the CDC issued a Level 2 travel alert for Guangdong Province, China, citing an outbreak of chikungunya, a mosquito-borne virus. Most cases have been reported in Foshan city. The disease is spread through mosquito bites and can cause fever, joint pain, headache, muscle pain, joint swelling or a rash. The CDC recommends two approved vaccines for those traveling to affected areas and encourages mosquito bite prevention measures, such as using insect repellent; wearing long-sleeved shirts and pants; and staying in places with air conditioning or that have screens on the windows and doors. Pregnant travelers are advised to reconsider travel to affected areas. Diphtheria in Guinea On July 22, the CDC announced a Level 2 travel alert for the Kankan region in Guinea due to confirmed and suspected cases of diphtheria. The CDC said vaccination against diphtheria was essential to protect against disease, urging travelers to ensure they are up to date on immunizations. Diphtheria symptoms include fever, sore throat, difficulty swallowing, change in voice, shortness of breath, weakness, or fatigue. The CDC advises travelers to avoid contact with people displaying symptoms. Clade II Mpox in Liberia and Sierra Leone The CDC issued another Level 2 alert on July 22 for Liberia and Sierra Leone due to outbreaks of clade II mpox. "Unlike the ongoing global clade II mpox outbreak that began in 2022, which has primarily affected gay, bisexual, and other men who have sex with men (MSM), these outbreaks have affected males and females approximately equally," said the alert. Transmission is occurring through close contact, including through sexual or other intimate contact. The CDC recommends travelers who anticipate intimate or sexual contact in affected areas are vaccinated. The CDC advises travelers to avoid contact with people who are sick with signs and symptoms of mpox, including those with skin or genital lesions. Those who develop new, unexplained skin rashes (lesions on any part of the body), with or without fever and chills, should seek immediate medical care. What Happens Next The CDC will continue tracking global outbreaks and will update its travel health notices as new information becomes available throughout the year.
New York Post
12 hours ago
- New York Post
The future of post-weight loss skincare starts at IMAGE with these new products
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. In the world of modern aesthetics, few developments have sparked as much excitement — and concern— as the widespread use of GLP-1 medications for rapid weight loss. These groundbreaking therapies have offered millions a renewed sense of health and well-being. Yet, for all their benefits, they often leave one visible drawback: their impact on the skin. Rapid fat loss, particularly in the face, can lead to noticeable changes in skin appearance, including volume deflation, deepening wrinkles, dryness and a loss of density. Recognizing this, IMAGE Skincare has introduced a pioneering solution: the first clinically formulated skincare product designed specifically to combat the four visible effects of GLP-1-induced weight loss on the skin. Created by board-certified plastic surgeon Dr. Marc Ronert, isn't your run-of-the-mill anti-aging product. It represents a new category of targeted skincare. Advertisement IMAGE Skincare At the heart of its innovation is the GLP-1 4D Skin Rebound Complex, a proprietary blend of active ingredients meticulously chosen to address the four primary signs of facial skin aging resulting from rapid weight loss: deflation, deep wrinkles, dehydration and density loss. Dr. Ronert's approach reflects an intersection of medical science and aesthetic care, backed by years of experience treating patients who sought solutions for the facial aging effects that often follow significant weight reduction. What makes so unique is its focus on restoring what the skin loses during accelerated fat loss. Facial deflation, a hallmark of GLP-1 therapy use, can age the appearance dramatically by hollowing the cheeks and under-eye areas. The advanced volumizing technology in helps to counteract this process, encouraging a more lifted, youthful contour. After 12 weeks of consistent, twice-daily use, instrumental grading revealed a 20% increase in facial volume, underscoring the product's efficacy in restoring fullness to areas most impacted by fat depletion. But volume is only one part of the equation. The skin's structure also suffers under the strain of rapid weight loss, often resulting in sagging and loss of elasticity. The GLP-1 4D Skin Rebound Complex targets these issues with ingredients designed to improve skin's bounce and resilience. What's more, the results speak for themselves. Clinical testing showed a 23% increase in net elasticity and a 22% improvement in firmness after 12 weeks — measurable results that translate to tighter, more supple skin. These improvements not only address the visual signs of aging but also help the skin maintain its integrity as the face adapts to a new, leaner shape. Deep wrinkles, another byproduct of reduced fat cushioning in the face, are also visibly diminished with As facial support structures weaken and the skin thins, fine lines evolve into pronounced creases. is engineered to fill and smooth these lines by encouraging collagen synthesis and enhancing moisture retention. Users experienced a 20% reduction in wrinkles over a 12-week period, with noticeable improvement often beginning as early as four weeks. This means that while the transformation unfolds gradually, early signs of success are visible quickly, reinforcing the importance of consistent use. Dehydration, though often overlooked, is a critical aspect of post-weight-loss skin care. Skin that loses volume also loses its ability to retain moisture efficiently, leading to a dull, tired complexion. combats this with deeply hydrating components that strengthen the skin barrier and improve water retention, leaving the skin plumper, more radiant and visibly revitalized. This comprehensive approach is what sets apart; rather than treating symptoms in isolation, it addresses the interconnected causes behind the accelerated aging many experience after GLP-1 usage. Why You Can Trust IMAGE Skincare IMAGE Skincare What further elevates this innovation is the credibility and care behind its creation. IMAGE Skincare, founded in 2003 by aesthetician Janna Ronert, has always prioritized products that merge clean, botanical ingredients with clinical efficacy. The collaboration between Janna and Dr. Marc Ronert brings together the precision of surgical insight and the sensitivity of professional skincare. Their shared vision has positioned IMAGE Skincare as a leader in science-driven, physician-formulated solutions that are also cruelty-free and accessible to both professionals and consumers. continues this legacy with a product that feels luxurious while performing like a professional-grade treatment. The Final Verdict IMAGE Skincare For those navigating the often-unexpected changes to their appearance following GLP-1 weight loss, offers a reassuring and effective remedy. So, you can toss away your other serum and moisturizer for the time being, as this restorative treatment, designed with a deep understanding of the unique biological changes occurring beneath the surface of the skin, is one to impress. Every application helps the face rediscover its definition, its structure and its glow. And ultimately, represents a major advancement in personalized skincare. It anticipates a need that is growing rapidly as more individuals turn to metabolic treatments for weight management, and it delivers on that need with unmatched precision and efficacy. With visible improvements in volume, elasticity, firmness and wrinkle reduction (all within just a few months!) users can expect a smoother, fuller, more youthful complexion that reflects their internal transformation — with consistent use. Backed by clinical testing and guided by medical expertise, proves that you don't have to choose between your health goals and your appearance. You can have both: resilient skin that rebounds, just like you. This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored.
